|Bid||0.135 x 0|
|Ask||0.145 x 0|
|Day's Range||0.135 - 0.145|
|52 Week Range||0.095 - 0.195|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, Sept. 21, 2018-- via NetworkWire– BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announces that it has selected ...
Scientific findings will discuss circulating tumor cells as a biomarker of tumor response, which is key to the advancement of BriaCell's BriaDX™, a diagnostic test designed to determine which patients are most likely to respond to treatment. NEW YORK, NY / ACCESSWIRE / September 21, 2018 / BriaCell Therapeutics Corp. (BCT.V) (OTCQB: BCTXF) ("BriaCell"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today it will present the data from biomarker analyses of its clinical trials for advanced breast cancer at the Fourth International Cancer Immunotherapy Conference as well as at The MicroCap Conference, both of which will take place in New York City.
SmallCapVoice.com, Inc. and BriaCell Therapeutics Corp. ("BriaCell") (BCT.V) (BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s President & CEO, Dr. William Williams, is featured in a new audio interview at SmallCapVoice.com, Inc. Dr. Williams, BriaCell’s President & CEO, called in to SmallcapVoice.com to go over the highlights for the Company’s achievements in the summer of 2018 and the expected newsflow from BriaCell in the coming months.
The addition of the Cancer Center of Kansas (CCK) as a new clinical trial site is expected to accelerate patient enrollment in both clinical trials. BERKELEY, Calif. and VANCOUVER, British Columbia, Aug. 08, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (“BriaCell”) (BCT.V) (BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that the Cancer Center of Kansas (CCK) has been added as a new clinical trial site. BriaCell is currently conducting an ongoing, multicenter, Phase IIa study of Bria-IMT™ (listed in ClinicalTrials.gov as NCT03066947) in advanced breast cancer, as well as the rollover combination study of Bria-IMT™ with pembrolizumab or ipilimumab (listed in ClinicalTrials.gov as NCT03328026).
TORONTO, ON / ACCESSWIRE / June 13, 2018 / BriaCell Therapeutics Corp. ("BriaCell") (BCT.V) (BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, will be presenting at this year's MicroCap Conference on June 21st in Toronto, Canada. Dr. Bill Williams, BriaCell's President and CEO will discuss Bria-IMT™, BriaCell's lead clinical candidate, its potential in treating breast cancer, and its advantages over similar immuno-oncology therapeutics.
In this article, I’m going to take a look at BriaCell Therapeutics Corp’s (TSXV:BCT) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
If you are a shareholder in BriaCell Therapeutics Corp’s (TSXV:BCT), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
LONDON, UK / ACCESSWIRE / February 16, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: Cronos Group, Antibe Therapeutics, ...
BriaCell Therapeutics Corp (TSXV:BCT), a CA$11.25M small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such asRead More...